Cancer Diagnostics

@article{Taube2005CancerD,
  title={Cancer Diagnostics},
  author={Sheila E. Taube and James W. Jacobson and Tracy G Lively},
  journal={American Journal of Pharmacogenomics},
  year={2005},
  volume={5},
  pages={357-364}
}
A new diagnostic tool must pass three major tests before it is adopted for routine clinical use. First, the tool must be robust and reproducible; second, the clinical value of the tool must be proven, i.e. the tool should reliably trigger a clinical decision that results in patient benefit; and, third, the clinical community has to be convinced of the need for this tool and the benefits it affords. Another factor that can influence the adoption of new tools relates to the cost and the vagaries… Expand
Small business development for molecular diagnostics.
TLDR
This chapter reviews the promise and challenges of business development in molecular diagnostics and guidelines are provided for the creation of a business model and the generation of a marketing plan around a candidate molecular diagnostic product. Expand
Proposals for a Phased Evaluation of Medical Tests
TLDR
A systematic search of the literature, a synthesis, and a critical review of phased evaluation schemes for medical tests show substantial similarity, suggesting that the evaluation of tests is most likely not a linear but a cyclic and repetitive process. Expand
Predictive biomarker validation in practice: lessons from real trials
TLDR
The merits and limitations of some of the clinical trial designs for predictive biomarker validation are discussed using examples from ongoing or completed clinical trials and some of these designs are discussed in the context of real trials. Expand
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
  • S. Mandrekar, D. Sargent
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
This work discusses and evaluates various clinical trial designs for the validation of biomarker-guided therapy and suggests that well-designed retrospective analysis from well-conducted prospective RCTs can bring forward effective treatments to marker-defined subgroups of patients in a timely manner. Expand
3D-Printed Immunosensor Arrays for Cancer Diagnostics
TLDR
This review offers a comprehensive description of 3D printing techniques commonly used to develop immunosensors, arrays, and microfluidic arrays and recent applications utilizing3D printing in immunos Sensors integrated with different signal transduction strategies are described. Expand
Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.
TLDR
The Trial Assessing IndiviuaLized Options for Treatment for breast cancer, a randomized trial of chemotherapy followed by hormonal therapy versus hormonal therapy alone on invasive disease-free survival-ductal carcinoma in situ (IDFS-DCIS) survival in women with node-negative, estrogen-receptor-positive breast cancer with a recurrence score of 11-25 is developed. Expand
Potential use of the comet assay in the clinical management of cancer.
TLDR
The potential of the comet assay as a tool for predicting an individual's tumour sensitivity to radiation and to various chemotherapeutic drugs is examined, as well as outlining the usefulness of the assay in assessing oxidative stress within tumours. Expand
Meta-analytic approaches for summarising and comparing the accuracy of medical tests
TLDR
Recommendations for use of valid methods and a reporting checklist were developed after it was found that inappropriate use of meta-analytic methods generated misleading results and conclusions in comparative reviews. Expand
Detecting Tumor Metastases: The Road to Therapy Starts Here.
TLDR
Various preclinical and clinical in vitro and in vivo assays developed to more efficiently detect tumor metastases are overview, which provides the foundation for developing more effective therapies for this invariably fatal component of the cancerous process. Expand
Biomarkers in Migraine Biomarkers in Migraine: Their Promise, Problems, and Practical Applications
TLDR
There are important limitations to the use of biomarkers in migraine, including problems with validity, reliability, accuracy, and precision. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 34 REFERENCES
Pharmacodiagnostic Testing in Breast Cancer
  • J. Bartlett
  • Medicine
  • American journal of pharmacogenomics : genomics-related research in drug development and clinical practice
  • 2005
TLDR
The biological and clinical rationale for targeting breast cancer with trastuzumab and the steps taken to validate and improve pharmacodiagnostic procedures for testing tumor HER2 protein expression and HER2 gene amplification are reviewed. Expand
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
TLDR
It was found that 18% of the community-based assays, which were used to establish the eligibility of patients to participate in the B-31 study, could not be confirmed by HercepTest IHC or fluorescence in situ hybridization (FISH) by a central testing facility. Expand
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
PURPOSE Metastatic breast cancer (MBC) is incurable; its treatment is palliative. We investigated whether the presence of circulating tumor cells (CTCs) predicts treatment efficacy, progression-freeExpand
Influence of unrecognized molecular heterogeneity on randomized clinical trials.
TLDR
Molecular heterogeneity, if it confers different risks to patients and is unaccounted for in the design of a randomized study, can result in a clinical trial that is underpowered and fails to detect a truly effective new therapy for cancer. Expand
Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?
TLDR
Clinical data do not support a relationship between EGFR expression and response to EGFR-targeted therapies cetuximab, gefitinib and erlotinib, and Histopathology will continue to be essential for unravelling the role of this enigmatic molecule and refining its status as a legitimate target in cancer therapy. Expand
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
TLDR
The poor concordance between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831, a prospective, randomized, three-arm, phase III trial for women with primary, operable, histologically confirmed, node-positive breast carcinoma. Expand
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
TLDR
The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients. Expand
A gene-expression signature as a predictor of survival in breast cancer.
TLDR
The gene-expression profile studied is a more powerful predictor of the outcome of disease in young patients with breast cancer than standard systems based on clinical and histologic criteria. Expand
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
TLDR
The immunohistochemical examination of ipsilateral axillary lymph nodes is a reliable, prognostically valuable, and simple method for the detection of occult nodal metastases and is recommended as a standard method of node examination in postmenopausal patients. Expand
Mammaglobin, a Breast‐Specific Gene, and Its Utility as a Marker for Breast Cancer
TLDR
It is demonstrated that the detection of mammaglobin protein and mRNA in clinical samples may be a useful marker for primary, metastatic, and occult breast cancer. Expand
...
1
2
3
4
...